Best Peptide Protocols
    GuideMar 5, 20269 min

    Subcutaneous vs Intramuscular vs Intranasal: Which Peptide Delivery Route Is Best?

    Route of administration determines bioavailability, onset speed, duration, and practical tolerability for every peptide on this site. A complete guide to understanding and choosing the right delivery method.

    Why Route of Administration Matters

    The same peptide administered via different routes can produce meaningfully different pharmacokinetic profiles — different peak blood levels, different onset times, different duration of action, and in some cases, different tissue distribution patterns. Understanding route differences is not just academic; it determines the practical design of a research protocol.

    The three primary routes used for peptide research on this site are:

  1. Subcutaneous (SC) — injection under the skin into the subcutaneous fat layer
  2. Intramuscular (IM) — injection directly into muscle tissue
  3. Intranasal — administration via the nasal mucosa

    4. A fourth route — oral — applies to the capsule products in the catalog and is addressed separately.

    Subcutaneous (SC): The Standard for Most Peptides

    Mechanism

    A subcutaneous injection deposits the peptide into the loose connective tissue and fat layer beneath the skin. This creates a depot effect — the peptide is absorbed gradually into local capillaries, producing a slower, more sustained rise in plasma concentration compared to IM.

    Characteristics

  4. Onset: 15–30 minutes (slower than IM)
  5. Duration: Longer plasma half-life from the depot effect
  6. Absorption: 75–95% bioavailability for most peptides via SC; approximates IM for most purposes
  7. Injection depth: 3–6 mm (using 29–31g, 5/16"–1/2" needle)
  8. Preferred sites: Abdomen (most consistent), thighs, upper arms; rotate sites to prevent lipodystrophy

    9. Which Peptides Use SC as Primary Route

    The vast majority of injectable peptides on this site are studied via subcutaneous injection:

  9. All GLP-1/2/3 peptides (Semaglutide, Tirzepatide, Retatrutide)
  10. BPC-157 (most common research route for systemic effects)
  11. TB-500
  12. Ipamorelin, CJC-1295, GHRP-6, Sermorelin, Tesamorelin
  13. Cagrilintide, Kisspeptin
  14. PT-141, Melanotan II
  15. GHK-Cu, MOTS-c, NAD+, Epithalon
  16. SS-31, LL-37, VIP

    17. Why SC Is Preferred

  17. Easiest to self-administer; least technique-sensitive
  18. Lower pain and bruising risk than IM
  19. Consistent absorption for most peptide molecular weights
  20. Standard used in the clinical trials that established dosing norms for GLP-1 drugs, tesamorelin, and other approved peptides

    21. Intramuscular (IM): When to Consider It

    Mechanism

    An intramuscular injection deposits peptide directly into muscle tissue, which has richer vascularization than subcutaneous fat. Absorption is faster and more complete — especially relevant for peptides with limited SC bioavailability.

    Characteristics

  21. Onset: 5–15 minutes (faster than SC)
  22. Duration: Shorter from faster clearance
  23. Bioavailability: Often equivalent to SC for most peptides; advantageous for some larger molecules
  24. Injection depth: 1–1.5 inches (longer needle, 25–27g) into large muscles (deltoid, vastus lateralis, gluteus medius)
  25. Technique sensitivity: Higher; incorrect placement increases bruising and discomfort risk

    26. Which Peptides May Use IM

  26. TB-500 (sometimes preferred for systemic distribution due to higher muscle concentration)
  27. BPC-157 (intra-articular is a distinct approach studied in joint research)
  28. Peptide blends targeting muscle tissue repair
  29. Some researchers prefer IM for NAD+ for faster onset

    30. Important Caveat

    For most GLP-1 and hormonal peptides, IM offers no advantage over SC and introduces more injection complexity. The SC route is standard because clinical trials used it — switching to IM without data supporting equivalence changes the research context.

    Intranasal: The CNS Access Route

    Mechanism

    Intranasal administration deposits peptide onto the nasal mucosa — a richly vascularized surface that provides rapid systemic absorption. More importantly, the olfactory region of the nasal mucosa provides a direct anatomical pathway to the CNS via the olfactory nerve, bypassing the blood-brain barrier that limits most peptides from reaching the brain systemically.

    Characteristics

  30. Onset: 15–30 minutes (rapid for CNS effects)
  31. Bioavailability: Variable; 30–80% for most peptides depending on molecular weight, nasal formulation, and administration technique
  32. CNS penetration: Substantially higher than SC/IM via the olfactory pathway
  33. Administration: Nasal spray or drops; usually 1–3 drops per nostril or 1 spray per nostril

    34. Which Peptides Are Studied via Intranasal Route

    This route is the primary or co-primary route for a specific subset of peptides where CNS access is the research target:

  34. Semax: Russian clinical practice uses intranasal; BDNF upregulation is a central nervous system effect. The spray formulation is RL's primary Semax product.
  35. Selank: Phase III clinical trials in Russia used intranasal administration; anxiolytic effects operate via CNS receptor modulation.
  36. DSIP (Delta Sleep-Inducing Peptide): Intranasal for sleep architecture effects
  37. Pinealon: Intranasal studied for neuroprotective and melatonin-regulatory effects

    38. BPC-157 Spray: A Special Case

    BPC-157 nasal spray is used primarily for its potential effects via nasal mucosa (GI tract-adjacent absorption for esophageal or upper GI research) and potentially direct CNS delivery for neuroprotective applications. It is not simply a substitute for injectable BPC-157 — it represents a different research angle.

    Delivery Route by Peptide Category

    CategoryStandard RouteNotes
    GLP-1/2/3 (weight loss)SubcutaneousClinical trial standard
    Growth hormone secretagoguesSubcutaneousPre-bedtime for GH pulse
    Recovery / healingSubcutaneousLocal site preferred for injuries
    Cognitive / nootropicIntranasalCNS access; clinical standard for Semax/Selank
    Sexual health (PT-141)SubcutaneousAlso studied intranasally (original PT-141 work)
    Anti-aging (NAD+, GHK-Cu)SubcutaneousSystemic distribution
    Immune / inflammationSubcutaneousSystemic distribution

    Practical Technique: Subcutaneous Injection Step-by-Step

  38. Wash hands thoroughly; prepare a clean surface
  39. Gather supplies: Reconstituted peptide vial, insulin syringe (29–31g, U-100), alcohol swabs
  40. Draw the dose: Insert needle into vial stopper; invert vial; draw to the required unit marking; remove air bubbles
  41. Select and prepare site: Most common is the abdomen (1–2 inches from the navel). Swab with alcohol; let dry 10–15 seconds
  42. Pinch skin: Grasp a small fold of skin and fat between thumb and forefinger
  43. Insert at 45°: For very thin subcutaneous layer, 45° angle; for standard adipose tissue, 90° is acceptable
  44. Inject slowly: Release the plunger steadily over 3–5 seconds
  45. Withdraw and apply light pressure: Remove needle at the same angle used for insertion; use a clean swab to apply gentle pressure (don't rub)
  46. Dispose of needle immediately in a sharps container

    47. Needle Size Selection

    UseGaugeLength
    Standard SC injection29–31g5/16" (8mm)
    Thin subcutaneous tissue29–31g5/16"
    IM (deltoid)25–27g1"
    IM (gluteus/thigh)25–27g1–1.5"
    Drawing from vial (mixing only)21–23g1"

    A 1 cc (1 mL) U-100 insulin syringe with a 29g needle handles 90%+ of subcutaneous peptide research injections. The 0.5 mL U-100 syringe is preferred when drawing very small volumes (under 0.3 mL) for accuracy.

    Common Route Errors

    Error 1: Using too long a needle for SC A 1-inch needle on a lean individual hits muscle — turning an intended SC injection into IM. Use 5/16" to 1/2" for subcutaneous.

    Error 2: Injecting too rapidly Rapid injection of subcutaneous fluid causes a painful wheal. Inject slowly over 3–5 seconds.

    Error 3: Not rotating sites Repeated SC injection in the same location causes lipodystrophy (fat atrophy or hypertrophy). Rotate systematically — a common system is clockwise around the abdomen.

    Error 4: Applying intranasal peptide incorrectly Intranasal administration requires the peptide to contact the olfactory mucosa (upper third of nasal cavity). Sniffing hard immediately after administration draws the peptide too far back into the throat, bypassing the olfactory region. Gentle, short insufflation or slow drops are preferred.

    Important Note

    This article is for educational and research reference purposes only. All administration should follow applicable research protocols and regulations. Consult a licensed healthcare provider for guidance on any medical application.